1.84
-0.41(-18.22%)
Currency In USD
Address
6500 Trans-Canada Highway
Pointe-Claire, QC H9R 0A5
Canada
Phone
514 426 6161
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
44
First IPO Date
February 15, 2022
| Name | Title | Pay | Year Born |
| Dr. Steve N. Slilaty Ph.D. | Chairman, President & Chief Executive Officer | 640,000 | 1952 |
| Dr. Abderrazzak Merzouki | Chief Operating Officer & Director | 340,000 | 1964 |
| Mr. Camille Sebaaly | Chief Financial Officer & Secretary | 695,000 | 1959 |
| Mr. Robert G. Ferreira | President of Sunshine Bio Investments Inc | 0 | 1962 |
| Mr. Malek Chamoun | Chief Development Officer | 0 | 1985 |
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.